Background/Objectives: We conducted an exploratory review of patients in our institutions who had undergone a PSMA PET/CT whilst on active surveillance, determining patient characteristics and trends. Methods: A retrospective cohort study of patients who were on active surveillance for low or favourable intermediate-risk prostate cancer and had a PSMA PET/CT done due to the presence of risk factors was performed. Risk factors that were an indication for PSMA PET/CT were: The presence of ISUP GG 2 disease, or ISUP GG1 disease with a PSA > 10 or a PI-RADS score of 4 or 5 on their MRI. Results: We identified 45 patients who underwent PSMA PET/CT whilst on active surveillance. Of these patients, 14 remained on active surveillance at the time of review, whilst 31 had progressed to definitive treatment. There was a significantly different distribution of PRIMARY scores between these two groups, although the average SUVMax was similar. In our practice, we found PSMA PET/CT to be particularly useful when performing confirmatory biopsies on patients who had normal MRI scans or were unable to go for the MRI at the time of diagnosis. Conclusions: PSMA PET/CT shows promise as a tool for active surveillance, particularly in men with risk factors for progressing to active treatment. However, our cohort was too small to draw definitive conclusions, and further research is needed.
Cancers. 2026 Apr 26*** epublish ***
Jonathon Carll, Jordan Santucci, Sarah Whitty, Jacinta Bonaddio, Marlon Perera, Dixon Teck Sing Woon, Mark Frydenberg, Nathan Lawrentschuk
EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3052, Australia., Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia., Department of Urology, Cabrini Cancer Institute, Melbourne, VIC 3144, Australia., Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia.